IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Single-dose pharmacokinetics and safety of iptakalim hydrochloride in Chinese healthy volunteers
Cai, Yun1; Chai, Dong1; Pei, Fei1; Fang, Yi3; Wang, Rui1; Liang, Bei-bei1; Cui, Wen-yu2,4; Bao, Cun-gang4; Wang, Hai2,4,5
关键词Food Effect Iptakalim Pharmacokinetics Phase i Safety
刊名JOURNAL OF PHARMACY AND PHARMACOLOGY
2012-03-01
DOI10.1111/j.2042-7158.2011.01411.x
64期:3页:337-343
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]PROTECTING ENDOTHELIAL FUNCTION ; POTASSIUM CHANNEL OPENERS ; ATP ; HYPERTENSION ; CELLS ; ACTIVATION ; PRESSURE
英文摘要

Objectives To investigate the safety, pharmacokinetics and food effect of iptakalim in healthy adult Han Chinese volunteers.

Methods Study 1 was a randomized open-label, Latin square designed, single-dose, three-period, self-control crossover study. Six men and six women received 5, 10 and 20 mg of iptakalim orally. Study 2 was a randomized, open-label, single-dose, two-period, self-control crossover study. Ten men were included and each subject received 5 mg iptakalim orally, fasting and nonfasting. Key findings No adverse effects were reported and no clinically meaningful changes in vital signs were found. Cmax, AUC(0-t) and AUC(0-infinity) were proportional over the dose levels of 5, 10 and 20 mg. Tmax, t1/2 and CL/F were similarly independent of dose level. In the 5 mg and 20 mg group, the Cmax, AUC0-t and AUC(0-infinity) in women were significantly higher than in men, although they showed no difference after correction by mg/kg doses in the 5 mg group. At the 5-mg dose level, no significant difference in pharmacokinetics was found in nonfasting and fasting subjects.

Conclusions Single-dose pharmacokinetics of iptakalim showed dose proportionality over the dose levels of 5-20 mg. The pharmacokinetics showed gender differences in the 5 and 20 mg groups. Food had almost no impact on the pharmacokinetics at the 5 mg level.

语种英语
WOS记录号WOS:000299889100003
项目编号2008ZX09101-006 ; D0204003040721 ; 02C26213200052
资助机构major national science and technology special projects for new drug ; major projects of Beijing science and technology ; national technical innovation projects
引用统计
被引频次:1[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/53717
专题北京大学第二临床医学院
作者单位1.Thadweik Acad Med, Beijing, Peoples R China
2.Tianjin Inst Hyg & Environm Med, Tianjin, Peoples R China
3.Peoples Liberat Army Gen Hosp, Dept Clin Pharmacol, Beijing 100853, Peoples R China
4.Peking Univ, Peoples Hosp, Dept Cardiovasc Pharmacol, Inst Pharmacol & Toxicol, Beijing 100871, Peoples R China
5.Peking Univ, Peoples Hosp, Dept Pharm, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Cai, Yun,Chai, Dong,Pei, Fei,et al. Single-dose pharmacokinetics and safety of iptakalim hydrochloride in Chinese healthy volunteers[J]. JOURNAL OF PHARMACY AND PHARMACOLOGY,2012,64(3):337-343.
APA Cai, Yun.,Chai, Dong.,Pei, Fei.,Fang, Yi.,Wang, Rui.,...&Wang, Hai.(2012).Single-dose pharmacokinetics and safety of iptakalim hydrochloride in Chinese healthy volunteers.JOURNAL OF PHARMACY AND PHARMACOLOGY,64(3),337-343.
MLA Cai, Yun,et al."Single-dose pharmacokinetics and safety of iptakalim hydrochloride in Chinese healthy volunteers".JOURNAL OF PHARMACY AND PHARMACOLOGY 64.3(2012):337-343.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Cai, Yun]的文章
[Chai, Dong]的文章
[Pei, Fei]的文章
百度学术
百度学术中相似的文章
[Cai, Yun]的文章
[Chai, Dong]的文章
[Pei, Fei]的文章
必应学术
必应学术中相似的文章
[Cai, Yun]的文章
[Chai, Dong]的文章
[Pei, Fei]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。